ID   NCI-H358
AC   CVCL_1559
SY   H358; H-358; NCIH358
DR   BTO; BTO:0002835
DR   CLO; CLO_0008085
DR   EFO; EFO_0002291
DR   CLDB; cl3656
DR   AddexBio; C0016016/4968
DR   ArrayExpress; E-MTAB-38
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-2706
DR   ArrayExpress; E-MTAB-2770
DR   ArrayExpress; E-MTAB-3610
DR   ATCC; CRL-5807
DR   BioGRID_ORCS_Cell_line; 964
DR   BioSample; SAMN03471313
DR   BioSample; SAMN10987886
DR   cancercelllines; CVCL_1559
DR   CCRID; 1101HUM-PUMC000470
DR   CCRID; 3101HUMTCHu151
DR   Cell_Model_Passport; SIDM00718
DR   ChEMBL-Cells; CHEMBL3307543
DR   ChEMBL-Targets; CHEMBL614135
DR   CLS; 300430
DR   Cosmic; 722039
DR   Cosmic; 724875
DR   Cosmic; 877106
DR   Cosmic; 903573
DR   Cosmic; 908465
DR   Cosmic; 910563
DR   Cosmic; 914944
DR   Cosmic; 929970
DR   Cosmic; 934545
DR   Cosmic; 980963
DR   Cosmic; 1004699
DR   Cosmic; 1028934
DR   Cosmic; 1032435
DR   Cosmic; 1052333
DR   Cosmic; 1146915
DR   Cosmic; 1219075
DR   Cosmic; 1239902
DR   Cosmic; 1600603
DR   Cosmic; 1741780
DR   Cosmic; 1802307
DR   Cosmic; 1870273
DR   Cosmic; 1995575
DR   Cosmic; 2042868
DR   Cosmic; 2560229
DR   Cosmic; 2630418
DR   Cosmic; 2647632
DR   Cosmic; 2668265
DR   Cosmic-CLP; 908465
DR   DepMap; ACH-000860
DR   ECACC; 95111733
DR   EGA; EGAS00001000610
DR   EGA; EGAS00001000978
DR   EGA; EGAS00001002554
DR   GDSC; 908465
DR   GEO; GSM108849
DR   GEO; GSM108850
DR   GEO; GSM206491
DR   GEO; GSM253398
DR   GEO; GSM274731
DR   GEO; GSM274732
DR   GEO; GSM385520
DR   GEO; GSM385531
DR   GEO; GSM434257
DR   GEO; GSM513937
DR   GEO; GSM514321
DR   GEO; GSM784251
DR   GEO; GSM794285
DR   GEO; GSM827468
DR   GEO; GSM844648
DR   GEO; GSM887427
DR   GEO; GSM888507
DR   GEO; GSM1374744
DR   GEO; GSM1670241
DR   IARC_TP53; 21571
DR   IARC_TP53; 21723
DR   IGRhCellID; NCIH358
DR   KCLB; 25807
DR   KCLB; 90358
DR   LiGeA; CCLE_423
DR   Lonza; 729
DR   PharmacoDB; NCIH358_1110_2019
DR   PRIDE; PXD030304
DR   Progenetix; CVCL_1559
DR   PubChem_Cell_line; CVCL_1559
DR   Wikidata; Q54908041
RX   PubMed=1311061;
RX   PubMed=1565469;
RX   PubMed=2388294;
RX   PubMed=2386953;
RX   PubMed=3335022;
RX   PubMed=3940644;
RX   PubMed=7972006;
RX   PubMed=8806092;
RX   PubMed=8806101;
RX   PubMed=9649128;
RX   PubMed=11030152;
RX   PubMed=11369051;
RX   PubMed=11464291;
RX   PubMed=12068308;
RX   PubMed=18083107;
RX   PubMed=19472407;
RX   PubMed=20164919;
RX   PubMed=20215515;
RX   PubMed=20557307;
RX   PubMed=22460905;
RX   PubMed=22961666;
RX   PubMed=24135919;
RX   PubMed=25485619;
RX   PubMed=25877200;
RX   PubMed=26589293;
RX   PubMed=27397505;
RX   PubMed=28196595;
RX   PubMed=29444439;
RX   PubMed=29681454;
RX   PubMed=30038707;
RX   PubMed=30894373;
RX   PubMed=30971826;
RX   PubMed=31068700;
RX   PubMed=31803961;
RX   PubMed=31978347;
RX   PubMed=34320349;
RX   PubMed=35117401;
RX   PubMed=35839778;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Part of: MD Anderson Cell Lines Project.
CC   Part of: NCI RAS program mutant KRAS cell line panel.
CC   Population: Caucasian.
CC   Doubling time: 38 hours (Note=In RPMI 1640 + 10% FBS), 76 hours (Note=In ACL-3), 60 hours (Note=In ACL-3 + BSA) (PubMed=3940644); 38 hours (PubMed=29681454); 38 hours (ECACC=95111733).
CC   HLA typing: A*03:01,03:01; B*15:01,35:01; C*03:04,04:01 (PubMed=26589293).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Gene deletion; HGNC; 11998; TP53; Zygosity=Homozygous (PubMed=1311061; PubMed=1565469; PubMed=20557307).
CC   Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Thr75Ala (c.223A>G); Zygosity=Heterozygous (PubMed=11464291; DepMap).
CC   Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Cys (c.34G>T); ClinVar=VCV000012578; Zygosity=Heterozygous (PubMed=1311061; PubMed=9649128; PubMed=12068308).
CC   Omics: CRISPR phenotypic screen.
CC   Omics: Deep exome analysis.
CC   Omics: Deep phosphoproteome analysis.
CC   Omics: Deep proteome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: Proteome analysis by 2D-DE/MS.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Genome ancestry: African=3.45%; Native American=0%; East Asian, North=4.63%; East Asian, South=0%; South Asian=0%; European, North=56.1%; European, South=35.82% (PubMed=30894373).
CC   Caution: NCI-H358 and NCI-H358M (Cellosaurus=CVCL_JA53) could be identical.
CC   Misspelling: H1358; PubMed=1311061; Note=In table 1.
CC   Discontinued: CLS; 300430; true.
CC   Derived from site: In situ; Lung; UBERON=UBERON_0002048.
CC   Cell type: Club cell; CL=CL_0000158.
ST   Source(s): AddexBio; ATCC; CCRID; CLS; Cosmic-CLP; ECACC; Genomics_Center_BCF_Technion; KCLB; PubMed=25877200
ST   Amelogenin: X,Y
ST   CSF1PO: 11,12
ST   D10S1248: 13,14
ST   D12S391: 20
ST   D13S317: 8,12
ST   D16S539: 12,13
ST   D18S51: 14
ST   D19S433: 13,14
ST   D1S1656: 15,15.3
ST   D21S11: 28,30
ST   D22S1045: 11,15
ST   D2S1338: 17,23
ST   D2S441: 11,15
ST   D3S1358: 14,18
ST   D5S818: 10,12
ST   D6S1043: 14
ST   D7S820: 10,11
ST   D8S1179: 13,14
ST   DYS391: 10
ST   FGA: 20,21
ST   Penta D: 10,13
ST   Penta E: 18
ST   TH01: 6
ST   TPOX: 8,9
ST   vWA: 17
DI   NCIt; C2923; Minimally invasive lung adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   Age unspecified
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 30-01-24; Version: 46
RX   PubMed=1311061;
RA   Mitsudomi T., Steinberg S.M., Nau M.M., Carbone D.P., D'Amico D.,
RA   Bodner S.M., Oie H.K., Linnoila R.I., Mulshine J.L., Minna J.D.,
RA   Gazdar A.F.;
RT   "p53 gene mutations in non-small-cell lung cancer cell lines and their
RT   correlation with the presence of ras mutations and clinical
RT   features.";
RL   Oncogene 7:171-180(1992).
RX   PubMed=1565469;
RA   Bodner S.M., Minna J.D., Jensen S.M., D'Amico D., Carbone D.P.,
RA   Mitsudomi T., Fedorko J., Buchhagen D.L., Nau M.M., Gazdar A.F.,
RA   Linnoila R.I.;
RT   "Expression of mutant p53 proteins in lung cancer correlates with the
RT   class of p53 gene mutation.";
RL   Oncogene 7:743-749(1992).
RX   PubMed=2388294; DOI=10.1093/jnci/82.17.1420;
RA   McLemore T.L., Litterst C.L., Coudert B.P., Liu M.C., Hubbard W.C.,
RA   Adelberg S., Czerwinski M.J., McMahon N.A., Eggleston J.C., Boyd M.R.;
RT   "Metabolic activation of 4-ipomeanol in human lung, primary pulmonary
RT   carcinomas, and established human pulmonary carcinoma cell lines.";
RL   J. Natl. Cancer Inst. 82:1420-1426(1990).
RX   PubMed=2386953;
RA   Gazdar A.F., Linnoila R.I., Kurita Y., Oie H.K., Mulshine J.L.,
RA   Clark J.C., Whitsett J.A.;
RT   "Peripheral airway cell differentiation in human lung cancer cell
RT   lines.";
RL   Cancer Res. 50:5481-5487(1990).
RX   PubMed=3335022;
RA   Alley M.C., Scudiero D.A., Monks A., Hursey M.L., Czerwinski M.J.,
RA   Fine D.L., Abbott B.J., Mayo J.G., Shoemaker R.H., Boyd M.R.;
RT   "Feasibility of drug screening with panels of human tumor cell lines
RT   using a microculture tetrazolium assay.";
RL   Cancer Res. 48:589-601(1988).
RX   PubMed=3940644;
RA   Brower M., Carney D.N., Oie H.K., Gazdar A.F., Minna J.D.;
RT   "Growth of cell lines and clinical specimens of human non-small cell
RT   lung cancer in a serum-free defined medium.";
RL   Cancer Res. 46:798-806(1986).
RX   PubMed=7972006; DOI=10.1073/pnas.91.23.11045;
RA   Okamoto A., Demetrick D.J., Spillare E.A., Hagiwara K., Hussain S.P.,
RA   Bennett W.P., Forrester K., Gerwin B.I., Serrano M., Beach D.H.,
RA   Harris C.C.;
RT   "Mutations and altered expression of p16INK4 in human cancer.";
RL   Proc. Natl. Acad. Sci. U.S.A. 91:11045-11049(1994).
RX   PubMed=8806092; DOI=10.1002/jcb.240630505;
RA   Phelps R.M., Johnson B.E., Ihde D.C., Gazdar A.F., Carbone D.P.,
RA   McClintock P.R., Linnoila R.I., Matthews M.J., Bunn P.A. Jr.,
RA   Carney D.N., Minna J.D., Mulshine J.L.;
RT   "NCI-Navy Medical Oncology Branch cell line data base.";
RL   J. Cell. Biochem. 63 Suppl. 24:32-91(1996).
RX   PubMed=8806101; DOI=10.1002/jcb.240630514;
RA   Lokshin A.E., Levitt M.L.;
RT   "Effect of suramin on squamous differentiation and apoptosis in three
RT   human non-small-cell lung cancer cell lines.";
RL   J. Cell. Biochem. 63 Suppl. 24:186-197(1996).
RX   PubMed=9649128; DOI=10.1038/bjc.1998.361;
RA   Yi S., Chen J.-R., Viallet J., Schwall R.H., Nakamura T., Tsao M.-S.;
RT   "Paracrine effects of hepatocyte growth factor/scatter factor on
RT   non-small-cell lung carcinoma cell lines.";
RL   Br. J. Cancer 77:2162-2170(1998).
RX   PubMed=11030152; DOI=10.1038/sj.onc.1203815;
RA   Modi S., Kubo A., Oie H.K., Coxon A.B., Rehmatulla A., Kaye F.J.;
RT   "Protein expression of the RB-related gene family and SV40 large T
RT   antigen in mesothelioma and lung cancer.";
RL   Oncogene 19:4632-4639(2000).
RX   PubMed=11369051; DOI=10.1016/S0165-4608(00)00363-0;
RA   Luk C., Tsao M.-S., Bayani J., Shepherd F.A., Squire J.A.;
RT   "Molecular cytogenetic analysis of non-small cell lung carcinoma by
RT   spectral karyotyping and comparative genomic hybridization.";
RL   Cancer Genet. Cytogenet. 125:87-99(2001).
RX   PubMed=11464291; DOI=10.1038/sj.onc.1204557;
RA   Shigemitsu K., Sekido Y., Usami N., Mori S., Sato M., Horio Y.,
RA   Hasegawa Y., Bader S.A., Gazdar A.F., Minna J.D., Hida T.,
RA   Yoshioka H., Imaizumi M., Ueda Y., Takahashi M., Shimokata K.;
RT   "Genetic alteration of the beta-catenin gene (CTNNB1) in human lung
RT   cancer and malignant mesothelioma and identification of a new 3p21.3
RT   homozygous deletion.";
RL   Oncogene 20:4249-4257(2001).
RX   PubMed=12068308; DOI=10.1038/nature00766;
RA   Davies H., Bignell G.R., Cox C., Stephens P.J., Edkins S., Clegg S.,
RA   Teague J.W., Woffendin H., Garnett M.J., Bottomley W., Davis N.,
RA   Dicks E., Ewing R., Floyd Y., Gray K., Hall S., Hawes R., Hughes J.,
RA   Kosmidou V., Menzies A., Mould C., Parker A., Stevens C., Watt S.,
RA   Hooper S., Wilson R., Jayatilake H., Gusterson B.A., Cooper C.S.,
RA   Shipley J.M., Hargrave D., Pritchard-Jones K., Maitland N.J.,
RA   Chenevix-Trench G., Riggins G.J., Bigner D.D., Palmieri G., Cossu A.,
RA   Flanagan A.M., Nicholson A., Ho J.W.C., Leung S.Y., Yuen S.T.,
RA   Weber B.L., Seigler H.F., Darrow T.L., Paterson H.F., Marais R.,
RA   Marshall C.J., Wooster R., Stratton M.R., Futreal P.A.;
RT   "Mutations of the BRAF gene in human cancer.";
RL   Nature 417:949-954(2002).
RX   PubMed=18083107; DOI=10.1016/j.cell.2007.11.025;
RA   Rikova K., Guo A.-L., Zeng Q.-F., Possemato A., Yu J., Haack H.,
RA   Nardone J., Lee K., Reeves C., Li Y., Hu Y.-R., Tan Z.-P., Stokes M.P.,
RA   Sullivan L., Mitchell J., Wetzel R., MacNeill J., Ren J.-M., Yuan J.,
RA   Bakalarski C.E., Villen J., Kornhauser J.M., Smith B., Li D.-Q.,
RA   Zhou X.-M., Gygi S.P., Gu T.-L., Polakiewicz R.D., Rush J., Comb M.J.;
RT   "Global survey of phosphotyrosine signaling identifies oncogenic
RT   kinases in lung cancer.";
RL   Cell 131:1190-1203(2007).
RX   PubMed=19472407; DOI=10.1002/humu.21028;
RA   Blanco R., Iwakawa R., Tang M.-Y., Kohno T., Angulo B., Pio R.,
RA   Montuenga L.M., Minna J.D., Yokota J., Sanchez-Cespedes M.;
RT   "A gene-alteration profile of human lung cancer cell lines.";
RL   Hum. Mutat. 30:1199-1206(2009).
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
RX   PubMed=20557307; DOI=10.1111/j.1349-7006.2010.01622.x;
RA   Iwakawa R., Kohno T., Enari M., Kiyono T., Yokota J.;
RT   "Prevalence of human papillomavirus 16/18/33 infection and p53
RT   mutation in lung adenocarcinoma.";
RL   Cancer Sci. 101:1891-1896(2010).
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
RX   PubMed=22961666; DOI=10.1158/2159-8290.CD-12-0112;
RA   Byers L.A., Wang J., Nilsson M.B., Fujimoto J., Saintigny P.,
RA   Yordy J., Giri U., Peyton M., Fan Y.-H., Diao L.-X., Masrorpour F.,
RA   Shen L., Liu W.-B., Duchemann B., Tumula P., Bhardwaj V., Welsh J.,
RA   Weber S., Glisson B.S., Kalhor N., Wistuba I.I., Girard L.,
RA   Lippman S.M., Mills G.B., Coombes K.R., Weinstein J.N., Minna J.D.,
RA   Heymach J.V.;
RT   "Proteomic profiling identifies dysregulated pathways in small cell
RT   lung cancer and novel therapeutic targets including PARP1.";
RL   Cancer Discov. 2:798-811(2012).
RX   PubMed=24135919; DOI=10.1038/ncomms3617;
RA   Balbin O.A., Prensner J.R., Sahu A., Yocum A., Shankar S., Malik R.,
RA   Fermin D., Dhanasekaran S.M., Chandler B., Thomas D., Beer D.G.,
RA   Cao X.-H., Nesvizhskii A.I., Chinnaiyan A.M.;
RT   "Reconstructing targetable pathways in lung cancer by integrating
RT   diverse omics data.";
RL   Nat. Commun. 4:2617.1-2617.13(2013).
RX   PubMed=25485619; DOI=10.1038/nbt.3080;
RA   Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S.,
RA   Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G.,
RA   Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J.,
RA   Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L.,
RA   Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J.,
RA   Settleman J., Seshagiri S., Zhang Z.-M.;
RT   "A comprehensive transcriptional portrait of human cancer cell
RT   lines.";
RL   Nat. Biotechnol. 33:306-312(2015).
RX   PubMed=25877200; DOI=10.1038/nature14397;
RA   Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M.,
RA   Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S.,
RA   Neve R.M.;
RT   "A resource for cell line authentication, annotation and quality
RT   control.";
RL   Nature 520:307-311(2015).
RX   PubMed=26589293; DOI=10.1186/s13073-015-0240-5;
RA   Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P.,
RA   Loewer M., Sahin U., Castle J.C.;
RT   "TCLP: an online cancer cell line catalogue integrating HLA type,
RT   predicted neo-epitopes, virus and gene expression.";
RL   Genome Med. 7:118.1-118.7(2015).
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
RX   PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005;
RA   Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P.,
RA   Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L.,
RA   Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D.,
RA   Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B.,
RA   Liang H.;
RT   "Characterization of human cancer cell lines by reverse-phase protein
RT   arrays.";
RL   Cancer Cell 31:225-239(2017).
RX   PubMed=29444439; DOI=10.1016/j.celrep.2018.01.051;
RA   Yuan T.L., Amzallag A., Bagni R., Yi M., Afghani S., Burgan W.,
RA   Fer N., Strathern L.A., Powell K., Smith B., Waters A.M., Drubin D.A.,
RA   Thomson T., Liao R., Greninger P., Stein G.T., Murchie E., Cortez E.,
RA   Egan R.K., Procter L., Bess M., Cheng K.T., Lee C.-S., Lee L.C.,
RA   Fellmann C., Stephens R., Luo J., Lowe S.W., Benes C.H.,
RA   McCormick F.;
RT   "Differential effector engagement by oncogenic KRAS.";
RL   Cell Rep. 22:1889-1902(2018).
RX   PubMed=29681454; DOI=10.1016/j.cell.2018.03.028;
RA   McMillan E.A., Ryu M.-J., Diep C.H., Mendiratta S., Clemenceau J.R.,
RA   Vaden R.M., Kim J.-H., Motoyaji T., Covington K.R., Peyton M.,
RA   Huffman K., Wu X.-F., Girard L., Sung Y., Chen P.-H., Mallipeddi P.L.,
RA   Lee J.Y., Hanson J., Voruganti S., Yu Y., Park S., Sudderth J.,
RA   DeSevo C., Muzny D.M., Doddapaneni H., Gazdar A.F., Gibbs R.A.,
RA   Hwang T.H., Heymach J.V., Wistuba I.I., Coombes K.R., Williams N.S.,
RA   Wheeler D.A., MacMillan J.B., DeBerardinis R.J., Roth M.G.,
RA   Posner B.A., Minna J.D., Kim H.S., White M.A.;
RT   "Chemistry-first approach for nomination of personalized treatment in
RT   lung cancer.";
RL   Cell 173:864-878.e29(2018).
RX   PubMed=30038707; DOI=10.18632/oncotarget.25642;
RA   Du L.-Q., Zhao Z.-Z., Suraokar M.B., Shelton S.S., Ma X.-Y., Hsiao T.-H.,
RA   Minna J.D., Wistuba I.I., Pertsemlidis A.;
RT   "LMO1 functions as an oncogene by regulating TTK expression and
RT   correlates with neuroendocrine differentiation of lung cancer.";
RL   Oncotarget 9:29601-29618(2018).
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
RX   PubMed=30971826; DOI=10.1038/s41586-019-1103-9;
RA   Behan F.M., Iorio F., Picco G., Goncalves E., Beaver C.M.,
RA   Migliardi G., Santos R., Rao Y., Sassi F., Pinnelli M., Ansari R.,
RA   Harper S., Jackson D.A., McRae R., Pooley R., Wilkinson P.,
RA   van der Meer D.J., Dow D., Buser-Doepner C.A., Bertotti A., Trusolino L.,
RA   Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.;
RT   "Prioritization of cancer therapeutic targets using CRISPR-Cas9
RT   screens.";
RL   Nature 568:511-516(2019).
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
RX   PubMed=31803961; DOI=10.1002/jcb.29564;
RA   Mulshine J.L., Ujhazy P., Antman M., Burgess C.M., Kuzmin I.A.,
RA   Bunn P.A. Jr., Johnson B.E., Roth J.A., Pass H.I., Ross S.M.,
RA   Aldige C.R., Wistuba I.I., Minna J.D.;
RT   "From clinical specimens to human cancer preclinical models -- a journey
RT   the NCI-cell line database-25 years later.";
RL   J. Cell. Biochem. 121:3986-3999(2020).
RX   PubMed=31978347; DOI=10.1016/j.cell.2019.12.023;
RA   Nusinow D.P., Szpyt J., Ghandi M., Rose C.M., McDonald E.R. III,
RA   Kalocsay M., Jane-Valbuena J., Gelfand E.T., Schweppe D.K.,
RA   Jedrychowski M.P., Golji J., Porter D.A., Rejtar T., Wang Y.K.,
RA   Kryukov G.V., Stegmeier F., Erickson B.K., Garraway L.A.,
RA   Sellers W.R., Gygi S.P.;
RT   "Quantitative proteomics of the Cancer Cell Line Encyclopedia.";
RL   Cell 180:387-402.e16(2020).
RX   PubMed=34320349; DOI=10.1016/j.celrep.2021.109441;
RA   Jochems F., Thijssen B., De Conti G., Jansen R., Pogacar Z., Groot K.,
RA   Wang L.-Q., Schepers A., Wang C., Jin H.-J., Beijersbergen R.L.,
RA   Leite de Oliveira R., Wessels L.F.A., Bernards R.;
RT   "The cancer SENESCopedia: a delineation of cancer cell senescence.";
RL   Cell Rep. 36:109441.1-109441.22(2021).
RX   PubMed=35117401; DOI=10.21037/tcr.2019.12.04;
RA   Hou W.-L., Chang M., Liu X.-F., Hu L.-S., Hua S.-C.;
RT   "Proteomic and ultrastructural analysis of Clara cell and type II
RT   alveolar epithelial cell-type lung cancer cells.";
RL   Transl. Cancer Res. 9:565-576(2020).
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).